At Miami Primary , we welcome the FDA and HHS’s recent decision to remove the outdated “black box” warning from many menopausal hormone therapies. This is an important and long-awaited step toward restoring confidence in a treatment that has helped countless women regain their health, balance, and quality of life. For more than 20 years, the black box warning—added in 2003 after early results from the Women’s Health Initiative (WHI)—has caused unnecessary fear and confusion a

Eli Lilly's new experimental weight-loss drug, retatrutide , is showing encouraging results in clinical trials by mimicking the effects...

Tirzepatide Significantly Lowers the Risk of Developing Type 2 Diabetes by 94% in Adults with Pre-Diabetes and Obesity Key Findings: -...